Research progress of indoleamine 2, 3-dioxygenase in renal disease

doi:10.3877/cma.j.issn.2095-3216.2021.04.007

Abstract

Abstract:

Indoleamine 2, 3-dioxygenase (IDO) is a key rate-limiting enzyme involved in tryptophane (TRP) degradation along the kynurenine (KYN) pathway. At present, it has been widely studied in the field of tumor, and is related to immunosuppression and immunoattenuation, which can promote the immune escape of tumors. Most renal diseases have underlying mechanisms of inflammation and immune system activation. IDO has been proven to alleviate renal inflammation and promote fibrosis in animal experiments, but its specific mechanism remains to be explored.This review summarized the possible action mechanisms of IDO in renal diseases.

Key words: Indoleamine 2, 3-dioxygenase, Renal disease

Lulu Liu, Xueli Lai, Wei Chen, Zhiyong Guo. Research progress of indoleamine 2, 3-dioxygenase in renal disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2021, 10(04): 224-226.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2021.04.007

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2021/V10/I04/224

Figures/Tables 1

References 30

[1]	Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance [J]. Trends Immunol, 2016, 37(3): 193-207.
[2]	Liu M, Wang X, Wang L, et al. Targeting the IDO1 pathway in cancer: from bench to bedside [J]. J Hematol Oncol, 2018, 11(1): 100.
[3]	Lim YJ, Foo TC, Yeung AWS, et al. Human indoleamine 2，3-dioxygenase 1 is an efficient mammalian nitrite reductase [J]. Biochemistry, 2019, 58(7): 974-986.
[4]	Ye Z, Yue L, Shi J, et al. Role of IDO and TDO in cancers and related diseases and the therapeutic implications [J]. J Cancer, 2019, 10(12): 2771-2782.
[5]	Li S, Li L, Wu J, et al. TDO promotes hepatocellular carcinoma progression [J]. Onco Targets Ther, 2020, 13: 5845-5855.
[6]	Labadie BW, Bao R, Luke JJ. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis [J]. Clin Cancer Res, 2019, 25(5): 1462-1171.
[7]	Liu K, Yang Y, Chen Y, et al. The therapeutic effect of dendritic cells expressing indoleamine 2，3-dioxygenase (IDO) on an IgA nephropathy mouse model [J]. Int Urol Nephrol, 2020, 52(2): 399-407.
[8]	Davison LM, Liu JC, Huang L, et al. Limited effect of indolamine 2，3-dioxygenase expression and enzymatic activity on lupus-like disease in B6.Nba2 mice [J]. Front Immunol, 2019, 10: 2017.
[9]	Hou W, Li S, Wu Y, et al. Inhibition of indoleamine 2, 3-dioxygenase-mediated tryptophan catabolism accelerates crescentic glomerulonephritis [J]. Clin Exp Immunol, 2009, 156(2): 363-372.
[10]	Matheus LHG, Simão GM, Amaral TA, et al. Indoleamine 2, 3-dioxygenase (IDO) increases during renal fibrogenesis and its inhibition potentiates TGF-β1-induced epithelial to mesenchymal transition [J]. BMC Nephrol, 2017, 18(1): 287.
[11]	Na N, Luo Y, Zhao D, et al. Prolongation of kidney allograft survival regulated by indoleamine 2, 3-dioxygenase in immature dendritic cells generated from recipient type bone marrow progenitors [J]. Mol Immunol, 2016, 79: 22-31.
[12]	Nakamura A, Nambu T, Ebara S, et al. Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response [J]. Proc Natl Acad Sci USA, 2018, 115(33): E7776-E7785.
[13]	Munn DH, Sharma MD, Baban B, et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2，3-dioxygenase [J]. Immunity, 2005, 22(5): 633-642.
[14]	Ravishankar B, Liu H, Shinde R, et al. The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity [J]. Proc Natl Acad Sci USA, 2015, 112(34): 10774-10779.
[15]	Okada A, Nangaku M, Jao TM, et al. D-serine, a novel uremic toxin, induces senescence in human renal tubular cells via GCN2 activation [J]. Sci Rep, 2017, 7(1): 11168.
[16]	Robertson LT, Trevino-Villarreal JH, Mejia P, et al. Protein and calorie restriction contribute additively to protection from renal ischemia reperfusion injury partly via leptin reduction in male mice [J]. J Nutr, 2015, 145(8): 1717-1727.
[17]	Chaudhary K, Shinde R, Liu H, et al. Amino acid metabolism inhibits antibody-driven kidney injury by inducing autophagy [J]. J Immunol, 2015, 194(12): 5713-5724.
[18]	Alzahrani AS. PI3K/Akt/mTOR inhibitors in cancer: at the bench and bedside [J]. Semin Cancer Biol, 2019, 59: 125-132.
[19]	Ye X, Ruan JW, Huang H, et al. PI3K-Akt-mTOR inhibition by GNE-477 inhibits renal cell carcinoma cell growth in vitro and in vivo [J]. Aging (Albany NY), 2020, 12(10): 9489-9499.
[20]	Lu Q, Wang WW, Zhang MZ, et al. ROS induces epithelial-mesenchymal transition via the TGF-β1/PI3K/Akt/mTOR pathway in diabetic nephropathy [J]. Exp Ther Med, 2019, 17(1): 835-846.
[21]	Ogiso H, Ito H, Ando T, et al. The deficiency of indoleamine 2，3-dioxygenase aggravates the CCl4-induced liver fibrosis in mice [J]. PLoS One, 2016, 11(9): e0162183.
[22]	Lee JW, Oh JE, Rhee KJ, et al. Co-treatment with interferon-γ and 1-methyl tryptophan ameliorates cardiac fibrosis through cardiac myofibroblasts apoptosis [J]. Mol Cell Biochem, 2019, 458(1-2): 197-205.
[23]	Li L, Wang T, Li S, et al. TDO2 promotes the EMT of hepatocellular carcinoma through Kyn-AhR pathway [J]. Front Oncol, 2020, 10: 562823.
[24]	Hao N, Whitelaw ML. The emerging roles of AhR in physiology and immunity [J]. Biochem Pharmacol, 2013, 86(5): 561-570.
[25]	Cheong JE, Sun L. Targeting the IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy - challenges and opportunities [J]. Trends Pharmacol Sci, 2018, 39(3): 307-325.
[26]	de Araújo EF, Feriotti C, Galdino NAL, et al. The IDO-AhR axis controls Th17/Treg immunity in a pulmonary model of fungal infection [J]. Front Immunol, 2017, 8: 880.
[27]	Itkin B, Breen A, Turyanska L, et al. New treatments in renal cancer: the AhR ligands [J]. Int J Mol Sci, 2020, 21(10): 3551.
[28]	Wang M, Hu HH, Chen YY, et al. Novel poricoic acids attenuate renal fibrosis through regulating redox signalling and aryl hydrocarbon receptor activation [J]. Phytomedicine, 2020, 79: 153323.
[29]	Liu JR, Miao H, Deng DQ, et al. Gut microbiota-derived tryptophan metabolism mediates renal fibrosis by aryl hydrocarbon receptor signaling activation [J]. Cell Mol Life Sci, 2021, 78(3): 909-922.
[30]	Moffett JR, Namboodiri MA. Tryptophan and the immune response [J]. Immunol Cell Biol, 2003, 81(4): 247-265.

Please choose a citation manager

Content to export